Remicade100mg

• Crohn's Disease (adults and pediatric)
• Ulcerative Colitis (adults and pediatric)
• Rheumatoid Arthritis (in combination with methotrexate)
• Ankylosing Spondylitis
• Psoriatic Arthritis
• Plaque Psoriasis

Adult Dose (IV Infusion):

• Crohn's Disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks; may increase to 10 mg/kg if loss of response
• Ulcerative Colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks
• Rheumatoid Arthritis: 3 mg/kg (with methotrexate) at 0, 2 and 6 weeks, then every 8 weeks; may increase to 10 mg/kg or every 4 weeks
• Ankylosing Spondylitis: 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks
• Psoriatic Arthritis & Plaque Psoriasis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks

Child Dose (IV Infusion):

• Crohn's Disease (6-17 years): 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks
• Ulcerative Colitis (6-17 years): 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks

Most Common (>10%):

• Infections (upper respiratory, sinusitis, pharyngitis)
• Infusion-related reactions
• Headache
• Abdominal pain

Others: Fever, chills, sweating, rash, pruritus

Precautions:

• Serious infections: Do not give during active infection; monitor and stop if infection becomes serious
• Invasive fungal infections: Consider empiric antifungal therapy for patients in endemic regions
• Malignancies: Incidence of malignancies including lymphoma was greater in infliximab treated patients
• Hepatitis B virus reactivation: Test for HBV before starting; monitor carriers during and after therapy
• Hepatotoxicity: Stop in cases of jaundice and/or marked liver enzyme elevations
• Heart failure: New onset or worsening symptoms may occur
• Cytopenias: Seek medical attention if signs develop; consider stopping infliximab
• Live vaccines or therapeutic infectious agents should not be given